Morepen Laboratories FY26 Results and Business Restructuring

Morepen Laboratories Limited has reported its financial results for the fourth quarter and full year ended March 31, 2026. The company announced a consolidated net profit of ₹94.88 crore for the fiscal year and ₹15.70 crore for the fourth quarter.

Key Financials and Dividend

The Board of Directors has recommended a final dividend of ₹0.20 per equity share. This payout offers a direct return to the company's shareholders.

Medical Devices Business Update

Significant progress has been made on the hive-off of the Medical Devices business to its subsidiary, Morepen Medipath Limited. The revised consideration for this transaction is ₹197.10 crore. The appointed date for this business transfer is set for April 1, 2026.

Strategic Realignment

This restructuring, particularly the separation of the Medical Devices business, is part of Morepen Laboratories' broader strategy to streamline operations and unlock value. The clarified consideration and revised appointed date offer greater certainty to investors regarding the company's strategic realignment.

Future Focus and Risks

Following the transfer, the company's focus is expected to shift to its remaining core businesses. Potential risks to monitor include the successful integration and future performance of Morepen Medipath Limited post-transfer, as well as any unforeseen delays in the hive-off process. Ensuring continued profitability in the core segments after the medical devices business disposal will also be a key factor.